Eyepoint Pharma (EYPT)
NASDAQ:EYPT
Want to see EYPT full AI Analyst Report?
Top Page
EyePoint Pharmaceuticals
(NASDAQ:EYPT)
Select Model
Select Model
Rating:47Neutral
Price Target:
$11.50
▼(-22.97% Downside)
Action:Reiterated
Date:05/14/26
Overall score reflects weak financial performance dominated by sharp revenue contraction, large operating losses, and significant cash burn. Pipeline updates and reiterated runway into Q4 2027 provide meaningful support, but the stock’s technical setup remains below key moving averages with negative MACD, and valuation metrics are constrained by negative earnings and no dividend yield data.
Positive Factors
Differentiated multi‑mechanism MOA and Phase II durability
DURAVYU’s multi-mechanism profile (VEGF, PDGF, JAK1/IL-6) and durable Phase II responses across >190 patients imply clinical differentiation versus pure anti‑VEGF biologics. That structural differentiation can support sustainable market share and pricing if pivotal data and approvals follow.
Negative Factors
Severe cash burn and negative operating cash flow
Sustained negative operating and free cash flow at this scale materially increases financing risk and the likelihood of dilution or costly external funding. Persistent cash burn also limits flexibility for commercial investment and raises execution risk if pivotal outcomes are delayed.
Read all positive and negative factors
Positive Factors
Negative Factors
Differentiated multi‑mechanism MOA and Phase II durability
DURAVYU’s multi-mechanism profile (VEGF, PDGF, JAK1/IL-6) and durable Phase II responses across >190 patients imply clinical differentiation versus pure anti‑VEGF biologics. That structural differentiation can support sustainable market share and pricing if pivotal data and approvals follow.
Read all positive factors
EyePoint Pharmaceuticals Key Performance Indicators (KPIs)
Any
Revenue Breakdown
Analyzes the sources of the company's revenue, highlighting key products or services that drive sales and indicating areas of growth or dependency.
Analyzes the sources of the company's revenue, highlighting key products or services that drive sales and indicating areas of growth or dependency.
Data provided by:
The Fly
The FlyEyePoint Pharmaceuticals (EYPT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.13B
Dividend YieldN/A
Average Volume (3M)899.10K
Price to Earnings (P/E)―
Beta (1Y)1.91
Revenue Growth-86.41%
EPS Growth-45.44%
CountryUS
Employees165
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.50
Shares Outstanding83,841,300
10 Day Avg. Volume912,752
30 Day Avg. Volume899,098
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)4.37
Price to Sales (P/S)42.66
P/FCF Ratio-5.50
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue141.09
Enterprise Value/Gross Profit184.41
Enterprise Value/Ebitda-3.86
Forecast
1Y Price Target
$36.40Price Target Upside143.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.5
Revenue Forecast (FY)$1.69M
EyePoint Pharmaceuticals Business Overview & Revenue Model
Company Description
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-...
How the Company Makes Money
EyePoint makes money primarily by commercializing ophthalmic products and by generating revenue from collaborations related to its drug delivery and product development activities. Product revenue is driven by sales of its marketed ophthalmic ther...
EyePoint Pharmaceuticals Earnings Call Summary
Earnings Call Date:May 06, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 05, 2026
Earnings Call Sentiment Positive
The call conveyed robust clinical and operational momentum: imminent Phase III wet AMD readouts, strong DME enrollment, favorable Phase II data and a differentiated MOA, supported by manufacturing and commercial preparations. Offsetting this are steep year-over-year revenue decline (driven by prior deferred revenue recognition), rising operating expenses, a larger quarterly net loss and a notable quarter-over-quarter cash reduction. Management projects cash runway into Q4 2027, and masked safety data and DSMC recommendations to date are favorable. Overall, the clinical and strategic positives tied to near-term pivotal catalysts moderately outweigh the financial headwinds.Positive Updates
Imminent Phase III Wet AMD Readouts
Top-line data for pivotal Phase III LUGANO expected mid-year 2026 with LUCIA to follow shortly thereafter; company positions DURAVYU to potentially be first-to-market among sustained-release programs.
Negative Updates
Sharp YoY Revenue Decline
Total net revenue was $0.7 million for Q1 2026 versus $24.5 million for Q1 2025, a decline of approximately 97.1%, primarily due to recognition of remaining deferred revenue related to the 2023 YUTIQ license agreement.
Read all updates
Q1-2026 Updates
Positive
Negative
Imminent Phase III Wet AMD Readouts
Top-line data for pivotal Phase III LUGANO expected mid-year 2026 with LUCIA to follow shortly thereafter; company positions DURAVYU to potentially be first-to-market among sustained-release programs.
Read all positive updates
Company Guidance
On the call EyePoint reiterated clear operational and clinical guidance with many specific metrics: the company ended Q1 2026 with $223M in cash and investments (down from $306M at 12/31/25) and expects that cash to fund operations into Q4 2027; Q1 net revenue was $0.7M vs. $24.5M a year earlier, operating expenses were $88M vs. $73M, and net loss was $85M ($0.99/share) vs. $45M ($0.65/share). Clinically, Phase III LUGANO top-line wet AMD data are expected mid‑2026 with LUCIA to follow shortly thereafter, DME trials COMO and CAPRI are >1/3 enrolled with a goal of full enrollment in both pivotal DME trials in Q3 2026 and DME top-line data expected H2 2027; both pivotal programs use identical non‑inferiority designs versus on‑label 2 mg aflibercept with 6‑month redosing. Other program metrics highlighted: DURAVYU has shown durable efficacy across >190 patients in 4 completed trials with no safety signals, a low discontinuation rate of ~5% (well below the ~10% annual wet AMD trial average), all LUGANO/LUCIA patients have reached week 32 with >35% having received a planned third dose at week 56, the independent DMC has issued 2 positive reviews with a third scheduled this month, the cGMP Northbridge facility has been online >1 year supporting anticipated CMC/NDA activities, and the combined U.S. branded wet AMD+DME market opportunity is nearly $15B.EyePoint Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
15
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.62M | 31.37M | 43.27M | 46.02M | 41.40M | 36.94M |
| Gross Profit | 5.83M | 29.30M | 39.56M | 41.39M | 33.08M | 28.76M |
| EBITDA | -278.42M | -243.43M | -129.23M | -69.00M | -96.62M | -50.15M |
| Net Income | -271.60M | -231.96M | -130.87M | -70.80M | -102.25M | -58.42M |
Balance Sheet | ||||||
| Total Assets | 288.22M | 364.00M | 418.46M | 355.18M | 180.36M | 263.37M |
| Cash, Cash Equivalents and Short-Term Investments | 222.54M | 306.09M | 370.91M | 331.05M | 144.56M | 211.56M |
| Total Debt | 20.23M | 20.77M | 21.86M | 4.91M | 46.35M | 39.20M |
| Total Liabilities | 57.74M | 57.88M | 81.96M | 88.86M | 83.99M | 78.99M |
| Stockholders Equity | 230.47M | 306.11M | 336.50M | 266.32M | 96.37M | 184.38M |
Cash Flow | ||||||
| Free Cash Flow | -271.54M | -243.39M | -130.28M | -1.61M | -67.16M | -50.25M |
| Operating Cash Flow | -267.54M | -240.11M | -126.23M | 1.88M | -65.00M | -50.10M |
| Investing Cash Flow | 88.11M | 68.58M | -219.35M | -3.31M | -17.27M | -33.12M |
| Financing Cash Flow | 171.98M | 173.65M | 164.02M | 187.07M | -690.00K | 216.90M |
EyePoint Pharmaceuticals Technical Analysis
Positive
14.93
Price Trends
13.44
Positive
14.34
Negative
14.03
Negative
Market Momentum
-0.14
Negative
53.51
Neutral
76.70
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EYPT, the sentiment is Positive. The current price of 14.93 is above the 20-day moving average (MA) of 13.17, above the 50-day MA of 13.44, and above the 200-day MA of 14.03, indicating a neutral trend. The MACD of -0.14 indicates Negative momentum. The RSI at 53.51 is Neutral, neither overbought nor oversold. The STOCH value of 76.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for EYPT.
EyePoint Pharmaceuticals Risk Analysis
EyePoint Pharmaceuticals disclosed 57 risk factors in its most recent earnings report. EyePoint Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
EyePoint Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $926.10M | -7.18 | 474.91% | ― | 131.13% | 35.61% | |
56 Neutral | $972.05M | 80.03 | 4.75% | ― | 15.66% | ― | |
53 Neutral | $1.40B | -10.60 | 121.52% | ― | 52.92% | 13.32% | |
52 Neutral | $2.89B | -29.43 | -41.54% | ― | 39.04% | 32.40% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.97B | -11.48 | -48.84% | ― | -83.20% | -439.48% | |
47 Neutral | $1.13B | -4.30 | -110.54% | ― | -86.41% | -45.44% |
* Healthcare Sector Average
EYPT
EyePoint Pharmaceuticals
13.58
6.34
87.57%
URGN
Urogen Pharma
28.13
23.89
563.44%
MGTX
Meiragtx Holdings
10.65
5.53
108.01%
STOK
Stoke Therapeutics
30.91
21.37
224.00%
TNGX
Tango Therapeutics
21.98
19.76
890.09%
PHAR
Pharming Group
12.99
2.09
19.17%
EyePoint Pharmaceuticals Corporate Events
Business Operations and StrategyProduct-Related Announcements
EyePoint Advances DURAVYU Phase 3 Wet AMD Program
Positive
May 14, 2026
On May 14, 2026, EyePoint reported that an independent Data Safety Monitoring Committee issued a third consecutive positive recommendation for its pivotal Phase 3 wet AMD program evaluating DURAVYU, allowing the LUGANO and LUCIA trials to continue...
Business Operations and StrategyProduct-Related Announcements
EyePoint Highlights DURAVYU Phase 3 Progress and Cash Runway
Positive
Apr 13, 2026
On April 13, 2026, EyePoint, Inc. posted an updated investor presentation outlining progress on DURAVYU, an investigational vorolanib intravitreal insert now in Phase 3 trials for wet AMD and DME. The company highlighted that its pivotal wet AMD t...
Business Operations and StrategyLegal Proceedings
EyePoint Sues Ocular Therapeutix Over Alleged Defamation
Negative
Mar 20, 2026
On March 20, 2026, EyePoint, Inc. filed a lawsuit in Middlesex County Superior Court in Massachusetts against Ocular Therapeutix, Inc., alleging the rival disseminated false or misleading statements about EyePoint and the clinical results of its l...
Business Operations and StrategyProduct-Related Announcements
EyePoint Starts Global Phase 3 Trials for DURAVYU
Positive
Mar 2, 2026
On March 2, 2026, EyePoint announced that the first patients have been dosed in its global Phase 3 COMO and CAPRI clinical trials evaluating DURAVYU for diabetic macular edema, signaling the start of pivotal late-stage testing in a major retinal i...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.